¿ Allos Therapeutics Inc., of Denver, completed enrollment in a Phase II trial of its lead drug candidate, RSR13, in patients with non-small-cell lung cancer undergoing chemotherapy followed by radiation therapy.
¿ AltaRex Corp., of Waltham, Mass., filed a final prospectus with the Ontario Securities Commission for an offering to raise C$7.8 million (US$5.3 million) by selling common shares at C$0.85 (US$0.57) per share.
¿ Alza Corp., of Mountain View, Calif., said the FDA approved its attention deficit hyperactivity disorder drug, Concerta (methylphenidate HCl). Alza exercised an option to license the drug from Crescendo Pharmaceuticals Corp., also of Mountain View, for an undisclosed fee based on worldwide sales.
¿ Collateral Therapeutics Inc., of San Diego, expanded a research collaboration with New York University covering the human angiogenic gene for fibroblast growth factor-4 (FGF-4), the gene utilized in Collateral's clinical-stage cardiovascular product Generx. The collaboration will now include the study of additional forms of FGF-4 and their interaction with biological receptors.
¿ ICAgen Inc., of Research Triangle Park, N.C., obtained a sole license for nervous-system-specific sodium channel gene technology from NPS Allelix Corp., of Toronto. In addition, the company obtained exclusive rights to store- or receptor-operated calcium channels from the University of California, Los Angeles.
¿ Intracel Inc., of Rockville, Md., said a study at The University of Nebraska Medical Center has shown the company's human monoclonal antibody-based product, HumaRAD, to be safe for the treatment of head and neck cancers. HumaRAD is designed to deliver a dose of radiation directly to tumors, and the company expects to evaluate the drug in additional trials.
¿ LifeTime Pharmaceuticals, of College Park, Md., reported success in two Phase I/II trials of Beta LT at McGill University's Jewish General Hospital in Montreal. Beta LT is an anticancer immune enhancement agent. The product was safe and evidence of biological effect was observed in more than half of patients.
¿ Morphochem AG, of Munich, Germany, raised EUR40 million (US$37.5 million) in a third-round oversubscribed private placement. Existing investors who participated were Techno Venture Management, Alta Partners, IKB Venture Capital, Alta Berkeley, Domain Associates and 3i Bioscience Investment Trust. New investors were led by Merlin BioSciences and included Nomura International, Julius Bar, West LB and Viscardi.
¿ Nexell Therapeutics Inc., of Irvine, Calif., obtained from NeoRx Corp., of Seattle, a 10-year exclusive license for all in vitro diagnostic applications of the NRLU-5 antibody, a cell surface marker common to many tumor types, including breast, lung, prostate and colon cancer.
¿ Onyx Pharmaceuticals Inc., of Richmond, Calif., agreed to a multiyear research collaboration wth EPPTCO Ltd., of Abingdon, U.K., to expand Onyx's anticancer Armed Therapeutic Virus platform. The agreement will allow Onyx to improve its anticancer viruses with the addition of prodrug-converting enzymes.
¿ Roche Inc., of Basel, Switzerland, submitted Tamiflu, developed in conjunction with Gilead Sciences Inc., of Foster City, Calif., for Japanese regulatory approval to treat A and B influenza viral infections. Tamiflu, which targets the neuraminidase protein, is approved for influenza treatment in the United States, Canada, Switzerland and in Latin America.
¿ SciClone Pharmaceuticals, of San Mateo, Calif., has begun marketing and distributing Zadaxin in Mexico. The product is approved for sale in 20 countries, principally for the treatment of hepatitis B and hepatitis C and as a vaccine adjuvant for patients with weakened immune systems.
¿ Vical Inc., of San Francisco, said results from Phase I and Phase II studies indicate Allovectin-7 is a safe treatment for early head and neck cancers. Allovectin-7, a DNA/lipid complex, contains the human gene that encodes HLB-B7, an immune-response triggering antigen.